|
Mouse Model for Specific Proteomic Labeling
Application
Proteomic labeling (labeling of proteins).
Key Benefits
Method can be used to express TurboID in any cell type.
The mouse line can be crossed with any existing Cre line and can be extended to any organ/tissue system.
Detection of labeled biomarkers can be identified in biofluids as biomarkers of cell specific disease mechanisms.
Can...
Published: 9/26/2024
Contributor(s): Srikant Rangaraju, Nicholas (Nick) Seyfried, Sruti Rayaprolu
|
|
Markers Predictive of Therapeutic Response in B-cell Malignancies
Application
Test to detect NF-kB2 breaks to guide treatment with proteasome inhibitors and its use with other therapeutic agents.
Key Benefits
Improved the prediction model to determine which patients are more likely to respond to bortezomib treatment.
Improved the efficacy of treatment for patients with multiple myeloma and lymphomas.
Market...
Published: 11/20/2024
Contributor(s): Leon Bernal-Mizrachi
|
|
Assays for Labeling and Evaluating Lysine Methylation
Application
A life science tool for evaluating protein lysine methylation for drug discovery and disease research.
Key Benefits
Highly specific labeling method for post-translational methylated lysine.
Potential to improve the understanding of protein lysine methylation and help develop new drugs to block its interactions across several disease...
Published: 11/20/2024
Contributor(s): Monika Raj, Ogonna Nwajiobi
|
|
Blood-based Diagnostic Test for Anxiety
Application
A blood-based biomarker test for the diagnosis of anxiety disorders.
Key Benefits
Gene panel of at least seven biomarkers that may predict anxiety in humans.
Minimally invasive blood test.
May identify different forms of anxiety leading to personalized treatment and improved clinical outcomes.
Market Summary
Anxiety disorders are...
Published: 11/20/2024
Contributor(s): Reid Alisch, Pankaj Chopra
|
|
Method and System for Recording and Recovery of Electrophysiology During Stimulation
Application
Systems and methods for recording and recovering viable electrophysiological signals and during delivery of stimulation, including deep brain stimulation (DBS).
Key Benefits
Enables the recording of electrophysiology/neurophysiology during stimulation from the same stimulating contact and adjacent contacts.
Enables the potential usage...
Published: 10/17/2024
Contributor(s): Enrico Opri, Svjetlana Miocinovic
|
|
A Predictive Marker and Treatment to Sensitize Multiple Myeloma Patients to Venetoclax (ABT-199)
Application
A marker that predicts Venetoclax (ABT-199) sensitivity that can also be targeted with a drug to help multiple myeloma patients.
Key Benefits
Marker that predicts if venetoclax will be an effective treatment in multiple myeloma patients.
A drug that targets venetoclax resistant multiple myeloma cells to improve treatment in patients.
Market...
Published: 7/30/2024
Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
|
|
Predicting Treatment Response in Patients with Spinal Muscular Atrophy (SMA)
Application
Prognostic model predicts treatment response to nusinersen (Spinraza®) in patients with spinal muscular atrophy.
Key Benefits
A prediction model using baseline CHOP-INTEND, IL-8, fractalkine, and MCP-1 accurately predicts CHOP-INTEND outcomes in children treated with nusinersen
The model can also be incorporated into future therapeutic...
Published: 11/20/2024
Contributor(s): William Hu, Sumit Verma
|
|
Theranostic Biomarker for Aspirin-Exacerbated Respiratory Disease
Application
Biomarkers for a clinical diagnostic tool and non-psychogenic therapy to detect and treat aspirin-exacerbated respiratory disease.
Key Benefits
Does not rely on aspirin challenge, increasing safety and availability for suspected patients.
May be used in patients who have respiratory compromise or are not stable.
Minimally-invasive...
Published: 9/26/2024
Contributor(s): Joshua Levy, Samuel Molina
|
|
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application
Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax.
Key Benefits
Co-therapy increases MM sensitivity to venetoclax treatment.
Identifies patients who will respond to venetoclax therapy.
Market Summary
Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody...
Published: 10/28/2024
Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
|
|
Targeting Peptide Improves Accurate Myocarditis Imaging and Diagnosis
ApplicationTargeting peptide molecule for image-based diagnosis of myocarditis.Key BenefitsEnables noninvasive diagnosis of myocarditis.Targets and binds to biomarker of myocarditis.Market SummaryMyocarditis is an inflammation of the heart muscle (myocardium). Myocarditis can affect your heart muscle and your heart's electrical system, reducing the...
Published: 7/30/2024
Contributor(s): Michael E. Davis, Mario Martinez
|
